Peptides DB
Research-centric peptide and protocol reference hub
Study 33 of 33Octreotide literaturebiorxiv-preprint · Observational

Management of Chylous Acid in Gynecological Malignancies

Management of chylous ascites should focus on monitoring drainage trends rather than relying on a single daily volume measurement.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the octreotide corpus
1
Preclinical
27
Observational · this one
0
Open-label
3
Randomised
2
Reviews

Summary and findings

This study evaluated the predictive value of daily drainage volume for the need for advanced interventions in patients with chylous ascites after lymphadenectomy. Of the 867 patients analyzed, 61 (7%) developed chylous ascites, with 9 (14.8%) requiring total parenteral nutrition and 7 (11.5%) requiring octreotide. The study found that a single daily drainage volume did not statistically predict the need for TPN.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
On postoperative day 4, median drainage output in TPN-requiring patients was 830 mL.

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p> <bold>Objectives:</bold> This study aimed to determine whether a single quantitative daily drainage cut-off volume could predict the need for advanced conservative interventions (TPN and octreotide) and to establish a structured conservative management strategy based on postoperative longitudinal drainage dynamics. <bold>Methods:</bold> Between June 2020 and April 2024, 867 patients undergoing lymphadenectomy were retrospectively analyzed. Patients developing CA were evaluated for baseline parameters, daily drainage patterns, serum protein levels, and management strategies. <bold>Results:</bold> CA developed in 61 (7%) patients. All were initially treated with a medium-chain triglyceride (MCT) diet. Due to persistent high-volume drainage, nine patients (14.8%) required total parenteral nutrition (TPN) and seven (11.5%) octreotide, typically on postoperative day (POD) 5. Patients requiring escalation demonstrated significantly higher baseline and interval drainage volumes than those managed with MCT diet alone (p < .05). On POD 4, median drainage output in TPN-requiring patients was 830 mL However, ROC analysis on POD 4 revealed that a single daily drainage volume did not provide a statistically significant cutoff threshold for predicting TPN requirement (AUC = 0.622, 95% CI: 0.429–0.815; <italic>p</italic> = .263). Consequently, therapeutic decisions relied on longitudinal drainage trends. These interventions led to clinical resolution within a median of 4-5 days post-initiation. Escalation were associated with longer median hospital stay (13 and 14 days, respectively, vs. 10 days; <italic>p</italic> < .05). <bold>Conclusion:</bold> Although POD 4 drainage volume was higher in patients requiring TPN (median 830 mL), ROC analysis did not identify a statistically significant cutoff threshold. Management of chylous ascites should be guided by comprehensive clinical monitoring of drainage trends from POD 1 to POD 3-4 alongside serum protein/globulin monitoring, rather than a single volumetric cutoff point. </p>

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Octreotide corpus

CThe role of biorelevant media components on the diffusion and enzymatic stability of oral cyclic peptide analogs.International journal of pharmaceutics · 2026 · Not reported in abstract.In vitroCActivation of the dopamine D2 receptor enhances colonic motility via disinhibition of somatostatinergic signalling in rodents.European journal of pharmacology · 2026 · Not reported in abstract.AnimalBMetastatic proinsulin-secreting tumor: a rare cause of persistent hypoglycemia.JCEM case reports · 2023 · n=1 · Not reported in abstract.HumanCThe Extent of Ligand-Receptor Interactions for Actively Targeted Nanoparticles as a Function of Ligand Density and Receptor Expression.ACS applied materials & interfaces · 2026 · Not reported in abstract.In vitroADifferential Somatostatin Sensitivity of Corticotropic and Somatotropic Responses Following Amino Acid Infusion.Endocrine connections · 2026 · Not reported in abstract.HumanBLesion-level Quantitative Post-therapy SPECT/CT During &lt;sup&gt;177&lt;/sup&gt;Lu-DOTATATE PRRT for NET Liver Metastases.Anticancer research · 2023 · n=12 · Lesion volume, kBq/ml max, and SUVmax significantly decreased from baseline to final evaluation (all p<0.01).Human